Taghreed earned her PhD in Cancer and Immunology from Claude Bernard University, France in December 2015 under the supervision of Professor Charles Dumontet. Her PhD studies focused on the examination of neutrophils effect on the sensitivity of lymphoma cells to anti-cancer agents. This work had demonstrated how neutrophils attenuate the sensitivity of lymphoma cells to a large variety of anti-cancer agents where similar findings were found in vivo and ex vivo (Hirz et. al, J Vis Exp. 2016; Hirz et. al, Oncotarget 2017).
After completing her PhD, Taghreed moved to The University of Texas MD Anderson Cancer Center for two years of postdoctoral studies on lung cancer, before recognizing her deeply founded interest in tumor microenvironment and immune system, that led her to Dr. David Scadden’s laboratory in April 2018. Taghreed is currently investigating the biology of prostate cancer and the complexity of the disease bone metastases, which represent glaring unmet medical knowledge to date. Through the utility of scRNA-sequencing, Taghreed seeks to illuminate the complex biology of prostate cancer and the heterogeneity of bone marrow microenvironment; including tumor, stromal, and immune cells; to produce novel insights relevant to tumor-stromal and tumor-immune interactions.